EVMN (31) IMRX (30) LFCR (59) CAMP (26) ⌘ Pro Terminal →

InflaRx N.V. (IFRX) — RQD Stock Rating Cockpit

$1.66 -3.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.65

InflaRx N.V. (IFRX) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $244.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IFRX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IFRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, InflaRx N.V. (NASDAQ: IFRX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $1.66 (-3.21% 1D, market cap $244.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IFRX ranks #220 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IFRX compare to EVMN and IMRX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IFRX carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EVMN (Evommune Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $244.2M) and IMRX (Immuneering Corporation (Class A)) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $242.5M). Among the 5-stock peer group, IFRX leads on earnings multiple (N/A) while EVMN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IFRX?

▼

For InflaRx N.V. (IFRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #220 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.65 (-0.77%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IFRX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (54/100 Composite)

🔍 WHY IFRX SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (24% of score)

FRED Regime × Technicals: 40% of 52W Range • RSI-14 at 49.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.55-0.6% Next Q

Q2 (-2Q)

Grade D$1.54+7.8% Next Q

Q3 (-1Q)

Grade C-$1.66+0% Next Q

Current

Grade D+$1.66-0.7% Hist 90D α

Trajectory: D (46) → D+ (54)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IFRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IFRX currently carries a cautious 54/100 (D+) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.85) and Max Pain ($1.74) forces dealer call-delta covering toward $3.10.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IFRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IFRX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 54%NO 46%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

49.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE40% OF RANGE

L: $1$1.66H: $3

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on IFRX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (48)

16/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like IFRX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IFRX)

✓Walkthrough of IFRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IFRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.07%▼ DESCENDING CHANNEL

2026-11-03O $1.71H $1.71L $1.66C $1.66VOL 691.5K

RES: $2.34SUP: $1.21SMA50: $1.85SMA200: $1.64

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IFRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IFRX Butterfly Map → + Track IFRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IFRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IFRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IFRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IFRX)

Health Care Rank #220 of 1016 ⚔️ EVMN vs IFRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IFRX vs. EVMN, IMRX, LFCR, CAMP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InflaRx N.V. (IFRX) ranks #220 by composite RQD confidence (54/100, grade D+) and #546 by equity capitalization ($244.6M). Within this direct 5-issuer industry benchmark cohort, IFRX leads on earnings valuation at N/A trailing P/E, while EVMN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with IFRX at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IFRX ACTIVE InflaRx N.V.	D+	54/100	—	—	—	-3.21%	$244.6M	Benchmark Subject
EVMN Evommune Inc.	E	31/100	—	—	-35.0%	-1.17%	$244.2M	/evmn-vs-ifrx →
IMRX Immuneering Corporation (Class A)	E	30/100	—	—	-35.0%	-6.84%	$242.5M	/imrx-vs-ifrx →
LFCR Lifecore Biomedical Inc.	C-	59/100	—	—	—	-1.84%	$242.3M	/lfcr-vs-ifrx →
CAMP CAMP4 Therapeutics Corporation	E	26/100	—	—	-35.0%	+1.54%	$248.5M	/camp-vs-ifrx →

2. IFRX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

InflaRx N.V. (IFRX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $244.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. IFRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IFRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IFRX compare to EVMN and IMRX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IFRX?

Where is IFRX trading relative to its 50-day, 200-day, and 52-week technical levels?

IFRX last traded at $1.66 (-3.21% on volume of 691,459 shares), positioning the stock -10.27% below its 50-day simple moving average ($1.85) and +1.22% above its 200-day simple moving average ($1.64). Across its 52-week range of $0.80 to $2.95, IFRX sits at the 40.0% percentile with a 14-day RSI of 49.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.45 to $1.87).

IFRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell IFRX stock right now?

InflaRx N.V. (IFRX) currently earns a Roarable Rating of D+ (Sell — SELL) with 54/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is IFRX's 12-month price target and RQD AI Jury consensus?

IFRX's 12-month base price target is $1.63 (range $1.27 to $3.1), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: IFRX RQD Cockpit IFRX 12M Forecast IFRX Earnings & Move IFRX Dividends & DRIP IFRX Insiders & 13F IFRX Whale Options IFRX Profit Sankey IFRX News & Why

ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IFRX — InflaRx N.V.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:17:06Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IFRX holds an RQD Score of 54 and a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars are scored as follows:

Fundamental Cash Engine: 12 / 20. The rating cites ROIC of 0% and FCF yield of 0%. For a prospective investor, this means the source data shows no measurable return on invested capital and no free-cash-flow yield supporting the current price. Any upside case must rest on future cash generation rather than present earnings power.
Whale 13F Flow: 7 / 20. This pillar reflects institutional accumulation and options positioning. The low score indicates weak institutional support in the source data, a factor that can amplify price moves in either direction for a stock of this size.
Insider Conviction: 9 / 20. This pillar reflects SEC Form 4 and Congressional PTR cluster flow. The below-midpoint score suggests insider activity is not a strong positive signal in the source data.
Macro Regime Fit: 13 / 20. Beta is 1.0, meaning the source data places the stock's market sensitivity at parity with the broad market. Sector sensitivity is factored in, but the rating does not isolate it further.
Forensic Balance Sheet: 13 / 20. The rating cites an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5. These are the strongest pillar readings, though they are mid-range rather than strong.

Taken together, the rating frames IFRX as a speculative, cash-flow-negative name whose balance sheet is the most defensible element. The investor implication is that valuation tradeoffs are unusually sensitive to future events, and the rating's "Trim" verdict signals that the weighted factors currently lean negative.

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items are tagged to IFRX:

Investor events (YELLOW, MARKET WIRE): A headline announces InflaRx investor events for November.
Price action (YELLOW / GREEN): Several headlines report intraday moves, including a rise to $1.60, a rise to $1.59, and a decline to $1.48. Each was published from 1h to 15h before the data timestamp.
Kidney data (YELLOW, MARKET WIRE): A headline states that InflaRx presented kidney data, with a market value cited at USD 254.9 million.
Catalyst-tagged items (GREEN, CATALYST): Two items carry the CATALYST impact label, both referencing price action with resistance-level language.

Risk watch items: several headlines are price-action or technical-pattern commentary from aggregator sites rather than company-issued disclosures, and their summaries contain no verified fundamental content. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. The only sector context provided is the Health Care / Biotechnology classification and the beta of 1.0. Not available in source data for any further ripple analysis.

Open Questions

What revenue, operating income, and net income have been reported by period, given that the financials section is empty?
What are the trailing and forward earnings and valuation multiples, which the market data marks as unavailable?
What is the status and timing of the November investor events and the kidney data referenced in the news feed?
Who holds the stock institutionally and through insider or congressional filings, given that holders data is absent?
What is the company's cash runway and debt schedule behind the rated Debt/Equity of 0.5?

IFRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for InflaRx N.V. (IFRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IFRX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 19h ago

InflaRx Announces November Investor Events

Yahoo Finance report covering InflaRx N.V. (IFRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 22h ago

InflaRx N.V. (IFRX) Climbs 4.58% to $1.60 as Shares Push Toward Resistance - High Yield Stocks

https://www.siam.in/ report covering InflaRx N.V. (IFRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

InflaRx N.V. (IFRX) Jumps 9.66% to $1.59 as Buyers Test Upper Resistance - Naked POC

https://www.dars.gov.et/ report covering InflaRx N.V. (IFRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

InflaRx presented kidney data. InflaRx stock stood at a USD 254.9 million market value.

ad-hoc-news.de report covering InflaRx N.V. (IFRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

InflaRx N.V. (IFRX) Slips 4.52% to $1.48, Drifting Toward the Lower End of Its Recent Range - Buffered ETF

https://www.dars.gov.et/ report covering InflaRx N.V. (IFRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

InflaRx presents kidney data. Needham sets USD 8.00 target for InflaRx stock

ad-hoc-news.de report covering InflaRx N.V. (IFRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

InflaRx presents kidney data for InflaRx stock investors

ad-hoc-news.de report covering InflaRx N.V. (IFRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 11d ago

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protectionStructural modeling provides new insight into izicopan’s differentiated molecular profile Jena, Germany, Oct. 22, 2026 (G

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IFRX Bull vs. Bear Conversation Board — What's Your Call at $1.66?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IFRX 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.86 (+8.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IFRX (D+ • RQD 54/100) a Buy at $1.72?

Welcome to the IFRX (InflaRx N.V.) Roar Pit. Current RQD Composite is 54/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.43 (-16.9%)

Spot @ $1.72

Pump the brakes on IFRX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IFRX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless InflaRx N.V. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.15 (+25.0%)

Spot @ $1.72

IFRX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IFRX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.72 (52-wk range $0.80 - $2.95), any beat on forward guidance forces shorts and underweight funds to chase.